`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner
`
`v.
`REGENERON PHARMACEUTICALS, INC.,
`Patent Owner
`
`
`Inter Partes Review No.: IPR2021-00881
`
`
`U.S. Patent No. 9,254,338 B2
`Filed: July 12, 2013
`Issued: February 9, 2016
`Inventor: George D. Yancopoulos
`
`Title: USE OF A VEGF ANTAGONIST TO TREAT
`ANGIOGENIC EYE DISORDERS
`
`
`PETITIONER MYLAN PHARMACEUTICALS INC.’S
`POWER OF ATTORNEY PURSUANT TO 37 C.F.R. § 42.10(b)
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.10(b), Petitioner Mylan Pharmaceuticals Inc.,
`
`hereby appoints the following practitioners as its attorneys to transact all business in
`
`the United States Patent & Trademark Office associated with its Petition for Inter
`
`Partes Review of U.S. Patent No. 9,254,338 B2:
`
`Lead Counsel
`Paul J. Molino (Reg. No. 45,350)
`paul@rmmslegal.com
`
`Postal and Hand Delivery Address
`Rakoczy Molino Mazzochi Siwik LLP
`6 West Hubbard Street
`Chicago, IL 60654
`Telephone: (312) 222-6300
`Facsimile: (312) 843-6260
`
`
`Petitioner consents to email service at:
`MYL_REG_IPR@rmmslegal.com
`
`Backup Counsel
`William A. Rakoczy
`(pro hac vice to be filed)
`wrakoczy@rmmslegal.com
`
`Heinz J. Salmen
`(pro hac vice to be filed)
`hsalmen@rmmslegal.com
`
`Neil B. McLaughlin (Reg. No. 70,810)
`nmclaughlin@rmmslegal.com
`
`Postal and Hand Delivery Address
`Rakoczy Molino Mazzochi Siwik LLP
`6 West Hubbard Street
`Chicago, IL 60654
`Telephone: (312) 527-5127
`Facsimile: (312) 843-6260
`
`
`The individual signing below has the authority to execute this document on
`
`
`
`
`
`behalf of Mylan Pharmaceuticals Inc.
`
`
`
`
`
`
`
`Mylan Pharmaceuticals Inc.
`
`By: ___________________________
`
`Name: _____Vinny Lee_______________
`
`Title: _____Litigation Counsel___________
`
`Date: _____May 4, 2021_______________
`
`
`
`
`
`2
`
`
`
`CERTIFICATE OF SERVICE
`The undersigned hereby certifies that a true and correct copy of the foregoing
`
`Petitioner Mylan Pharmaceuticals Inc.’s Power of Attorney Pursuant to 37 C.F.R. §
`
`42.10(b) was served on May 5, 2021, via FedEx Priority Overnight on the Patent
`
`Owner at the correspondence address of record for U.S. Patent No. 9,254,338 B2 as
`
`evidenced in Public Pair:
`
`
`
`
`
`
`
`Regeneron – Bozicevic Field & Francis LLP
`201 Redwood Shores Parkway
`Suite 200
`Redwood City, CA 94065
`
`Regeneron Pharmaceuticals, Inc.
`770 Old Saw Mill River Road
`Tarrytown, NY 10591
`
`/Paul J. Molino/
`Paul J. Molino (Reg. No. 45,350)
`
`
`
`
`
`